ReviewBritish journal of pharmacology2012
Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction.
Review in British journal of pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 122 citations in OpenAlex.
- Trial
- FTO Deficiency Inhibits Vascular Endothelial Cell Apoptosis and Improved Mitophagy in Obesity-Related Hypertension by Enhancing NDRG1 m6A Methylation.Biochemical genetics · 2026Article
- Potassium channels in vascular smooth muscle cells.Physiological reviews · 2026Review
- Single-center experience using Endologix anatomically fixated endograft device for treatment of aortoiliac occlusive disease.Journal of vascular surgery cases and innovative techniques · 2026Article
- Hypercoagulability in Cushing's syndrome: past, present, future.Archives of endocrinology and metabolism · 2025Review
- Does a heritable common latent factor explain body mass index, percent body fat, and waist circumference across childhood?International journal of obesity (2005) · 2025Article
- Coronary Microvascular Dysfunction in Ischaemic Heart Disease: Lessons From Large Animal Models.Basic & clinical pharmacology & toxicology · 2025Review
- Therapeutic Potential of Infrared and Related Light Therapies in Metabolic Diseases.International journal of molecular sciences · 2025Review
- Associations between daytime napping, sleep duration, and depression and 15 cardiovascular diseases: a Mendelian randomization study.Cardiovascular diagnosis and therapy · 2024Article
- Differential hemodynamic adaptations to tilt test in patients with idiopathic atrial fibrillation.Physiological reports · 2024Article
- Article
- Cardiometabolic profiles and proteomics associated with obesity phenotypes in a longitudinal cohort of young adults.Scientific reports · 2024Article
- Neural circuits of long-term thermoregulatory adaptations to cold temperatures and metabolic demands.Nature reviews. Neuroscience · 2024Review
- The Association between Mid-Upper Arm Circumference and Blood Pressure in an Italian Population of School-Aged Children and Adolescents with Lipid Disorders.Journal of clinical medicine · 2024Article
- Molecular regulators of exercise-mediated insulin sensitivity in non-obese individuals.Journal of cellular and molecular medicine · 2024Review
- Obesity and hypertension: Obesity medicine association (OMA) clinical practice statement (CPS) 2023.Obesity pillars · 2023Article
- Perivascular adipose tissue and adipocyte-derived exosomal miRNAs maintain vascular homeostasis.Heliyon · 2023Review
- The Increase in Childhood Obesity and Its Association with Hypertension during Pandemics.Journal of clinical medicine · 2023Review
- The Influence of Antioxidants on Oxidative Stress-Induced Vascular Aging in Obesity.Antioxidants (Basel, Switzerland) · 2023Review
- Microbiome Dysbiosis: A Pathological Mechanism at the Intersection of Obesity and Glaucoma.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledObesity has become a serious global health issue affecting both adults and children. Recent devolopments in world demographics and declining health status of the world's population indicate that the prevalence of obesity will continue to increase in the next decades. As a disease, obesity has deleterious effects on metabolic homeostasis, and affects numerous organ systems including heart, kidney and the vascular system. Thus, obesity is now regarded as an independent risk factor for atherosclerosis-related diseases such as coronary artery disease, myocardial infarction and stroke. In the arterial system, endothelial cells are both the source and target of factors contributing to atherosclerosis. Endothelial vasoactive factors regulate vascular homeostasis under physiological conditions and maintain basal vascular tone. Obesity results in an imbalance between endothelium-derived vasoactive factors favouring vasoconstriction, cell growth and inflammatory activation. Abnormal regulation of these factors due to endothelial cell dysfunction is both a consequence and a cause of vascular disease processes. Finally, because of the similarities of the vascular pathomechanisms activated, obesity can be considered to cause accelerated, 'premature' vascular aging. Here, we will review some of the pathomechanisms involved in obesity-related activation of endothelium-dependent vasoconstriction, the clinical relevance of obesity-associated vascular risk, and therapeutic interventions using 'endothelial therapy' aiming at maintaining or restoring vascular endothelial health. LINKED ARTICLES: This article is part of a themed section on Fat and Vascular Responsiveness. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.